FDAsafety guidance54% confidence
Novel Drug Approvals for 2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (asthma) as Breztri Gains US Approval as First Triple Therapy for Asthma.
Regulatory Analysis
Novel Drug Approvals for 2026
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Asthma
Related signal: Breztri Gains US Approval as First Triple Therapy for Asthma